Kosuke Tanaka

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 3

Top Topics

Placebo Controlled

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Scott Murray, Takahiro Higashibata, Takaomi Kessoku, Shinya Kajiura, Mami Hirakawa, Shunsuke Oyamada, Keisuke Ariyoshi, Takeshi Yamada, Yoshiyuki Yamamoto, Yasuyuki Takashima, Kosuke Doki, Masato Homma, Bryan J Mathis, Tsumugi Jono, Tomoki Ogata, Kosuke Tanaka, Yuki Kasai, Michihiro Iwaki, Akiko Fuyuki, Atsushi Nakajima, Ryuji Hayashi, Takayuki Ando, Naoki Izawa, Yuko Kobayashi, Yoshiki Horie, Tatsuya Morita
Naldemedine for Opioid-Induced Constipation in Patients With Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Kosuke Tanaka, Takaomi Kessoku, Atsushi Yamamoto, Kota Takahashi, Yuki Kasai, Anna Ozaki, Michihiro Iwaki, Takashi Kobayashi, Tsutomu Yoshihara, Noboru Misawa, Takayuki Kato, Jun Arimoto, Akiko Fuyuki, Eiji Sakai, Takuma Higurashi, Hideyuki Chiba, Kunihiro Hosono, Masato Yoneda, Tomoyuki Iwasaki, Takeo Kurihashi, Machiko Nakatogawa, Ayao Suzuki, Masataka Taguri, Shunsuke Oyamada, Keisuke Ariyoshi, Noritoshi Kobayashi, Yasushi Ichikawa, Hirokazu Takahashi
Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation. BMJ open 12 (5) (2022)
Michihiro Iwaki, Takaomi Kessoku, Kosuke Tanaka, Anna Ozaki, Yuki Kasai, Atsushi Yamamoto, Kota Takahashi, Takashi Kobayashi, Asako Nogami, Yasushi Honda, Yuji Ogawa, Kento Imajo, Masato Yoneda, Noritoshi Kobayashi, Satoru Saito, Hirokazu Takahashi
Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study. BMJ open 12 (7) (2022)